NASDAQ:HTGM - Nasdaq - US40434H3021 - Common Stock - Currency: USD
0.48
-0.12 (-20%)
The current stock price of HTGM is 0.48 USD. In the past month the price decreased by -81.32%. In the past year, price decreased by -92.79%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
VEEV | VEEVA SYSTEMS INC-CLASS A | 36.13 | 36.66B | ||
DOCS | DOXIMITY INC-CLASS A | 56.54 | 13.58B | ||
WAY | WAYSTAR HOLDING CORP | N/A | 7.26B | ||
CERT | CERTARA INC | 33.77 | 2.12B | ||
TDOC | TELADOC HEALTH INC | N/A | 1.98B | ||
GDRX | GOODRX HOLDINGS INC-CLASS A | 15.03 | 1.83B | ||
SDGR | SCHRODINGER INC | N/A | 1.65B | ||
PHR | PHREESIA INC | N/A | 1.64B | ||
EVH | EVOLENT HEALTH INC - A | 15.8 | 1.22B | ||
HSTM | HEALTHSTREAM INC | 50.58 | 999.88M | ||
LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 966.46M | ||
DH | DEFINITIVE HEALTHCARE CORP | 14.47 | 762.50M |
HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. The company is headquartered in Tucson, Arizona and currently employs 53 full-time employees. The company went IPO on 2015-05-06. The firm is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. The firm is engaged in the sales of its HTG EdgeSeq system and integrated next-generation sequencing-based (NGS-based) HTG EdgeSeq research use only (RUO) assays and from sample processing services. Its HTG EdgeSeq profiling technology measures ribonucleic acid (RNA) using deoxyribonucleic acid (DNA) nuclease protection probes (DNA protection probes). Its profiling product and service solutions enable targeted RNA profiling using a small amount of biological sample, in liquid or solid forms. Its menu of HTG EdgeSeq assays includes the HTG Transcriptome Panel (HTP), which is designed to measure approximately 20,000 mRNA targets using its HTG EdgeSeq technology, is automated on its HTG EdgeSeq system.
HTG MOLECULAR DIAGNOSTICS
3430 E Global Loop
Tucson ARIZONA 85706 US
CEO: John L. Lubniewski
Employees: 53
Company Website: https://www.htgmolecular.com/
Phone: 18772892615.0
The current stock price of HTGM is 0.48 USD. The price decreased by -20% in the last trading session.
The exchange symbol of HTG MOLECULAR DIAGNOSTICS is HTGM and it is listed on the Nasdaq exchange.
HTGM stock is listed on the Nasdaq exchange.
7 analysts have analysed HTGM and the average price target is 6.12 USD. This implies a price increase of 1175% is expected in the next year compared to the current price of 0.48. Check the HTG MOLECULAR DIAGNOSTICS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
HTG MOLECULAR DIAGNOSTICS (HTGM) has a market capitalization of 1.06M USD. This makes HTGM a Nano Cap stock.
HTG MOLECULAR DIAGNOSTICS (HTGM) currently has 53 employees.
The Revenue of HTG MOLECULAR DIAGNOSTICS (HTGM) is expected to grow by 0.6% in the next year. Check the estimates tab for more information on the HTGM EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
HTGM does not pay a dividend.
HTG MOLECULAR DIAGNOSTICS (HTGM) will report earnings on 2023-08-09, after the market close.
HTG MOLECULAR DIAGNOSTICS (HTGM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.15).
ChartMill assigns a fundamental rating of 2 / 10 to HTGM. Both the profitability and financial health of HTGM have multiple concerns.
Over the last trailing twelve months HTGM reported a non-GAAP Earnings per Share(EPS) of -18.15. The EPS increased by 44.99% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | 7.1 |
ChartMill assigns a Buy % Consensus number of 83% to HTGM. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 81.55% and a revenue growth 0.6% for HTGM